4/A: Allarity Therapeutics Executive Receives RSU Grant

Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, was granted 133,333 restricted stock units.

Summary

• Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, Inc. (ALLR), received a grant of 133,333 restricted stock units (RSUs).
• The grant occurred on January 28, 2026, under the company's Amended and Restated 2021 Equity Incentive Plan.
• Following this transaction, the reporting person's total beneficial ownership of common stock increased to 381,644 shares.
• The RSUs are subject to a three-year vesting schedule, with one-third vesting annually on the anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which carries a neutral sentiment for investors.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership personnel via a multi-year vesting schedule.

Negatives

• Potential for future shareholder dilution upon the vesting and issuance of the underlying common stock.

Risks

• Vesting is contingent upon the reporting person's continued relationship with the issuer, creating potential turnover risk if the executive departs before the full vesting period.

Future Outlook

The RSUs will vest in equal one-third installments on January 28, 2027, 2028, and 2029, provided the reporting person maintains their relationship with the company.

Industry Context

StockSavvy.ai notes that equity grants to C-suite executives in the biotechnology sector are standard practice for aligning management incentives with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of a three-year vesting schedule for RSUs is consistent with standard corporate governance practices for small-cap biotechnology firms.
• Equity-based compensation remains the primary mechanism for executive retention in the high-risk, high-reward pharmaceutical development industry.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual settlement of the RSUs into common stock.

Next Steps

• Vesting of the first tranche of RSUs on January 28, 2027.

Key Dates

Keywords

Allarity Therapeutics, ALLR, Form 4, Insider Trading, Equity Incentive Plan, Restricted Stock Units